1887

Microbial Genomics logo

Volume 9, Issue 7

Population structure, serotype distribution and antibiotic resistance of causing invasive disease in Victoria, Australia Open Access

Abstract

is a major human pathogen and can cause a range of conditions from asymptomatic colonization to invasive pneumococcal disease (IPD). The epidemiology and distribution of IPD-causing serotypes in Australia has undergone large changes following the introduction of the 7-valent pneumococcal conjugate vaccine (PCV) in 2005 and the 13-valent PCV in 2011. In this study, to provide a contemporary understanding of the IPD causing population in Victoria, Australia, we aimed to examine the population structure and prevalence of antimicrobial resistance using whole-genome sequencing and comprehensive antimicrobial susceptibility data of 1288 isolates collected between 2018 and 2022. We observed high diversity among the isolates with 52 serotypes, 203 sequence types (STs) and 70 Global Pneumococcal Sequencing Project Clusters (GPSCs) identified. Serotypes contained in the 13v-PCV represented 35.3 % (=405) of isolates. Antimicrobial resistance (AMR) to at least one antibiotic was identified in 23.8 % (=358) of isolates with penicillin resistance the most prevalent (20.3 %, =261 using meningitis breakpoints and 5.1 % =65 using oral breakpoints). Of the AMR isolates, 28 % (=101) were multidrug resistant (MDR) (resistant to three or more drug classes). Vaccination status of cases was determined for a subset of isolates with 34 cases classified as vaccine failure events (fully vaccinated IPD cases of vaccine serotype). However, no phylogenetic association with failure events was observed. Within the highly diverse IPD population, we identified six high-risk sub-populations of public health concern characterized by high prevalence, high rates of AMR and MDR, or serotype inclusion in vaccines. High-risk serotypes included serotypes 3, 19F, 19A, 14, 11A, 15A and serofamily 23. In addition, we present our data validating seroBA for serotyping to facilitate ISO-accreditation of this test in routine use in a public health reference laboratory and have made this data set available. This study provides insights into the population dynamics, highlights non-vaccine serotypes of concern that are highly resistant, and provides a genomic framework for the ongoing surveillance of IPD in Australia which can inform next-generation IPD prevention strategies.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): population genomics and Streptococcus pneumonaie
Funding
This study was supported by the:
  • National Health and Medical Research Council (Award 1149991)
    • Principle Award Recipient: P HowdenBenjamin
© 2023 The Authors
  • This is an open-access article distributed under the terms of the Creative Commons Attribution License. This article was made open access via a Publish and Read agreement between the Microbiology Society and the corresponding author’s institution.
Loading

Article metrics loading...

/content/journal/mgen/10.1099/mgen.0.001070
2023-07-20
2024-04-27
Loading full text...

Full text loading...

/deliver/fulltext/mgen/9/7/mgen001070.html?itemId=/content/journal/mgen/10.1099/mgen.0.001070&mimeType=html&fmt=ahah

References

  1. Weiser JN, Ferreira DM, Paton JC. Streptococcus pneumoniae: transmission, colonization and invasion. Nat Rev Microbiol 2018; 16:355–367 [View Article] [PubMed]
     [Google Scholar]
  2. Global Pneumococcal Disease and Vaccination | CDC; 2022 https://www.cdc.gov/pneumococcal/global.html accessed 3 August 2022
  3. Pneumonia. n.d https://www.who.int/news-room/fact-sheets/detail/pneumonia accessed 3 August 2022
  4. Toms C, de Kluyver R. Enhanced invasive Pneumococcal disease surveillance working group for the communicable diseases network Australia. invasive Pneumococcal disease in Australia, 2011 and 2012. Commun Dis Intell Q Rep 2016E267–E284
     [Google Scholar]
  5. 23-Valent Pneumococcal polysaccharide vaccine. WHO position paper. Releve Epidemiol Hebd 2008; 83:373–384
     [Google Scholar]
  6. Fitzgerald D, Waterer GW. Invasive Pneumococcal and Meningococcal disease. Infect Dis Clin North Am 2019; 33:1125–1141 [View Article] [PubMed]
     [Google Scholar]
  7. Barry C, Krause VL, Cook HM, Menzies RI. Invasive Pneumococcal disease in Australia 2007 and 2008. Commun Dis Intell Q Rep 2012; 36:E151–E165 [PubMed]
     [Google Scholar]
  8. Health AGD of. Pneumococcal disease The Australian Immunisation Handbook; 2018 https://immunisationhandbook.health.gov.au/vaccinepreventable-diseases/pneumococcal-disease accessed 28 January 2021
  9. Pennington K. Enhanced invasive Pneumococcal disease surveillance working group, communicable diseases network Australia. invasive Pneumococcal disease surveillance, 1 July to 30 September 2019. Commun Dis Intell 2020; 44: [View Article]
     [Google Scholar]
  10. Park SY, Van Beneden CA, Pilishvili T, Martin M, Facklam RR et al. Invasive Pneumococcal infections among vaccinated children in the United States. J Pediatr 2010; 156:478–483 [View Article] [PubMed]
     [Google Scholar]
  11. Croucher NJ, Chewapreecha C, Hanage WP, Harris SR, McGee L et al. Evidence for soft selective sweeps in the evolution of Pneumococcal multidrug resistance and vaccine escape. Genome Biol Evol 2014; 6:1589–1602 [View Article] [PubMed]
     [Google Scholar]
  12. Croucher NJ, Finkelstein JA, Pelton SI, Mitchell PK, Lee GM et al. Population genomics of post-vaccine changes in Pneumococcal epidemiology. Nat Genet 2013; 45:656–663 [View Article] [PubMed]
     [Google Scholar]
  13. Brueggemann AB, Pai R, Crook DW, Beall B. Vaccine escape recombinants emerge after Pneumococcal vaccination in the United States. PLoS Pathog 2007; 3:e168 [View Article] [PubMed]
     [Google Scholar]
  14. Croucher NJ, Kagedan L, Thompson CM, Parkhill J, Bentley SD et al. Selective and genetic constraints on Pneumococcal serotype switching. PLoS Genet 2015; 11:e1005095 [View Article] [PubMed]
     [Google Scholar]
  15. Hansman D, Bullen MM. A resistant Pneumococcus. The Lancet 1967; 290:264–265 [View Article]
     [Google Scholar]
  16. Collignon PJ, Bell JM, the A. Drug‐resistant Streptococcus pneumoniae: the beginning of the end for many antibiotics?. Med J Aust 1996; 164:64–67 [View Article]
     [Google Scholar]
  17. Fenoll A, Ardanuy C, Liñares J, Cercenado E, Marco F et al. Serotypes and genotypes of S. pneumoniae isolates from adult invasive disease in Spain: a 5-year prospective surveillance after pediatric PCV13 licensure. The ODIN study. Vaccine 2018; 36:7993–8000 [View Article] [PubMed]
     [Google Scholar]
  18. Ruhe JJ, Myers L, Mushatt D, Hasbun R. High-level penicillin-nonsusceptible Streptococcus pneumoniae bacteremia: identification of a low-risk subgroup. Clin Infect Dis 2004; 38:508–514 [View Article] [PubMed]
     [Google Scholar]
  19. Ho PL, Lam KF, Chow FKH, Lau YL, Wong SSY et al. Serotype distribution and antimicrobial resistance patterns of nasopharyngeal and invasive Streptococcus pneumoniae isolates in Hong Kong children. Vaccine 2004; 22:3334–3339 [View Article] [PubMed]
     [Google Scholar]
  20. Gladstone RA, Lo SW, Lees JA, Croucher NJ, van Tonder AJ et al. International genomic definition of pneumococcal lineages, to contextualise disease, antibiotic resistance and vaccine impact. EBioMedicine 2019; 43:338–346 [View Article] [PubMed]
     [Google Scholar]
  21. Epping L, van Tonder AJ, Gladstone RA, Bentley SD, Page AJ et al. The global Pneumococcal sequencing consortium null, Bentley SD, Page AJ, et al. SeroBA: rapid high-throughput serotyping of Streptococcus pneumoniae from whole genome sequence data. Microb Genom 2018; 4:e000204 [View Article] [PubMed]
     [Google Scholar]
  22. Snapshot of Australia, 2021 | Australian Bureau of Statistics; 2022 https://www.abs.gov.au/statistics/people/people-and-communities/snapshot-australia/latest-release accessed 5 April 2023
  23. Communicable Diseases Network Australia. Invasive pneumococcal disease: Australian national notifiable diseases case definition; 2004 https://www.health.gov.au/resources/publications/invasive-pneumococcal-disease-surveillance-case-definition accessed 3 April 2023
  24. CLSI Performance Standards for Antimicrobial Susceptibility Testing, M100. 31st ed Wayne, PA: Clinical and Laboratory Standards Institute; 2022
     [Google Scholar]
  25. Souvorov A, Agarwala R, Lipman DJ. SKESA: strategic k-mer extension for scrupulous assemblies. Genome Biol 2018; 19:153 [View Article] [PubMed]
     [Google Scholar]
  26. Habib M, Porter BD, Satzke C. Capsular serotyping of Streptococcus pneumoniae using the Quellung reaction. J Vis Exp JoVE 2014e51208 [View Article] [PubMed]
     [Google Scholar]
  27. Jolley KA, Bray JE, Maiden MCJ. Open-access bacterial population genomics: BIGSdb software, the PubMLST.org website and their applications. Wellcome Open Res 2018; 3:124 [View Article] [PubMed]
     [Google Scholar]
  28. Lees JA, Harris SR, Tonkin-Hill G, Gladstone RA, Lo SW et al. Fast and flexible bacterial genomic epidemiology with PopPUNK. Genome Res 2019; 29:304–316 [View Article] [PubMed]
     [Google Scholar]
  29. Sherry NL, Horan KA, Ballard SA, Gonҫalves da Silva A, Gorrie CL et al. An ISO-certified genomics workflow for identification and surveillance of antimicrobial resistance. Nat Commun 2023; 14:60 [View Article] [PubMed]
     [Google Scholar]
  30. Feldgarden M, Brover V, Gonzalez-Escalona N, Frye JG, Haendiges J et al. AMRFinderPlus and the reference gene catalog facilitate examination of the genomic links among antimicrobial resistance, stress response, and virulence. Sci Rep 2021; 11:12728 [View Article] [PubMed]
     [Google Scholar]
  31. Nguyen L-T, Schmidt HA, von Haeseler A, Minh BQ. IQ-TREE: a fast and effective stochastic algorithm for estimating maximum-likelihood phylogenies. Mol Biol Evol 2015; 32:268–274 [View Article] [PubMed]
     [Google Scholar]
  32. Schliep KP. phangorn: phylogenetic analysis in R. Bioinforma Oxf Engl 2011; 27:592–593 [View Article] [PubMed]
     [Google Scholar]
  33. Yu G, Smith DK, Zhu H, Guan Y, Lam TTY. Ggtree: an R package for visualization and annotation of phylogenetic trees with their covariates and other associated data. Methods Ecol Evol 2017; 8:28–36 [View Article]
     [Google Scholar]
  34. Wickham H, Averick M, Bryan J, Chang W, McGowan L et al. Welcome to the Tidyverse. J Open Source Softw 2019; 4:1686 [View Article]
     [Google Scholar]
  35. Conway JR, Lex A, Gehlenborg N, Hancock J. UpSetR: an R package for the visualization of intersecting sets and their properties. Bioinformatics 2017; 33:2938–2940 [View Article] [PubMed]
     [Google Scholar]
  36. Rockett RJ, Oftadeh S, Bachmann NL, Timms VJ, Kong F et al. Genome-wide analysis of Streptococcus pneumoniae serogroup 19 in the decade after the introduction of pneumococcal conjugate vaccines in Australia. Sci Rep 2018; 8:16969 [View Article] [PubMed]
     [Google Scholar]
  37. Golden AR, Adam HJ, Karlowsky JA, Baxter M, Schellenberg J et al. Genomic investigation of the most common Streptococcus pneumoniae serotypes causing invasive infections in Canada: the SAVE study, 2011-2020. J Antimicrob Chemother 2023; 78:i26–i36 [View Article] [PubMed]
     [Google Scholar]
  38. Lo SW, Gladstone RA, van Tonder AJ, Lees JA, du Plessis M et al. Pneumococcal lineages associated with serotype replacement and antibiotic resistance in childhood invasive pneumococcal disease in the post-PCV13 era: an international whole-genome sequencing study. Lancet Infect Dis 2019; 19:759–769 [View Article] [PubMed]
     [Google Scholar]
  39. Sheppard CL, Groves N, Andrews N, Litt DJ, Fry NK et al. The genomics of Streptococcus pneumoniae carriage isolates from UK children and their household contacts, Pre-PCV7 to Post-PCV13. Genes 2019; 10:687 [View Article] [PubMed]
     [Google Scholar]
  40. Azarian T, Mitchell PK, Georgieva M, Thompson CM, Ghouila A et al. Global emergence and population dynamics of divergent serotype 3 CC180 pneumococci. PLoS Pathog 2018; 14:e1007438 [View Article] [PubMed]
     [Google Scholar]
  41. Choi EH, Zhang F, Lu Y-J, Malley R, Burns DL. Capsular Polysaccharide (CPS) release by serotype 3 Pneumococcal strains reduces the protective effect of Anti-Type 3 CPS antibodies. Clin Vaccine Immunol 2016; 23:162–167 [View Article] [PubMed]
     [Google Scholar]
  42. van Tonder AJ, Bray JE, Quirk SJ, Haraldsson G, Jolley KA et al. Putatively novel serotypes and the potential for reduced vaccine effectiveness: capsular locus diversity revealed among 5405 pneumococcal genomes. Microb Genom 2016; 2:000090 [View Article] [PubMed]
     [Google Scholar]
  43. Kapatai G, Sheppard CL, Troxler LJ, Litt DJ, Furrer J et al. Pneumococcal 23B molecular subtype identified using whole genome sequencing. Genome Biol Evol 2017; 9:2122–2135 [View Article] [PubMed]
     [Google Scholar]
  44. Hawkins PA, Chochua S, Lo SW, Belman S, Antonio M et al. A global genomic perspective on the multidrug-resistant Streptococcus pneumoniae 15A-CC63 sub-lineage following pneumococcal conjugate vaccine introduction. Microb Genom 2023; 9:mgen000998 [View Article] [PubMed]
     [Google Scholar]
  45. Savinova T, Brzhozovskaya E, Shagin D, Mikhaylova Y, Shelenkov A et al. A multiple drug-resistant Streptococcus pneumoniae of serotype 15A occurring from serotype 19A by capsular switching. Vaccine 2020; 38:5114–5118 [View Article] [PubMed]
     [Google Scholar]
  46. Yang Baek J, Kim SH, Kang C-I, Chung DR, Peck KR et al. Emergence of an extensively drug-resistant (XDR) Streptococcus pneumoniae serotype 15A by capsular switching. Int J Med Microbiol 2018; 308:986–989 [View Article] [PubMed]
     [Google Scholar]
  47. Hao L, Kuttel MM, Ravenscroft N, Thompson A, Prasad AK et al. Streptococcus pneumoniae serotype 15B polysaccharide conjugate elicits a cross-functional immune response against serotype 15C but not 15A. Vaccine 2022; 40:4872–4880 [View Article] [PubMed]
     [Google Scholar]
  48. Egorova E, Kumar N, Gladstone RA, Urban Y, Voropaeva E et al. Key features of pneumococcal isolates recovered in Central and Northwestern Russia in 2011-2018 determined through whole-genome sequencing. Microb Genom 2022; 8:mgen000851 [View Article] [PubMed]
     [Google Scholar]
  49. Demczuk W, Martin I, Griffith A, Lefebvre B, McGeer A et al. Linear regression equations to predict β-lactam, macrolide, lincosamide, and fluoroquinolone MICs from molecular antimicrobial resistance determinants in Streptococcus pneumoniae. Antimicrob Agents Chemother 2022; 66:e0137021 [View Article] [PubMed]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/mgen/10.1099/mgen.0.001070
Loading
Population structure, serotype distribution and antibiotic resistance of Streptococcus pneumoniae causing invasive disease in Victoria, Australia
M Gen 9, 001070 (2023); https://doi.org/10.1099/mgen.0.001070
/content/journal/mgen/10.1099/mgen.0.001070
/content/journal/mgen/10.1099/mgen.0.001070
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF

Supplementary material 2

EXCEL

Supplementary material 3

EXCEL

Supplementary material 4

EXCEL

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error